Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.
Diana Bitner, MD, MSCP, FACOG
Advertisement
Articles by Diana Bitner, MD, MSCP, FACOG
Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
A Look at Lynkuet® (Elinzanetant) for the Treatment of Moderate to Severe Vasomotor Symptoms
2
Facility-Based CRC Screening Nearly 10-Fold Higher in 45- to 49-Year-Olds After Guideline Changes
3
Nonstimulant Pharmacotherapy for ADHD: A Clinical Update for Primary Care
4
Lisa Larkin, MD: Elinzanetant Offers a “Game-Changing” Option for Menopause Care in Primary Care
5
